While this chart is useful, you may be asking yourself – What does this all mean?! Let us go through several examples.
About Sara Hathaway, PharmD
After graduating from UW-Madison's School of Pharmacy with my PharmD, I spent my first eight years at an independent pharmacy dividing my time between both retail and long-term care. I fell in love with the independent pharmacy world and joined the PAAS team to help independents not only survive, but thrive.
I enjoy assisting pharmacy staff both pre- and post-audit and enjoy providing them with knowledge and tools to decrease audit risk going forward. I write articles for Third-Party Newsline each month and answer member questions daily. I look forward to building professional relationships with each of our members and assisting you with your next audit.
Entries by Sara Hathaway, PharmD
As pharmacies across the country are gaining access to this anti-viral COVID-19 therapeutic agent, it is important to understand the specifications of the EUA…
There has been a sharp increase in the number of Targeted Probe and Educate Program audits on diabetic testing supplies.
Ever wonder if you were billing the correct NDC for a Humira® prescription and had to spend precious time investigating? Or how about questioning if you were billing the correct package size for Gvoke® and had to consult multiple references just to try and figure out the answer?
Manufacturers go through rigorous testing to bring their products to market and part of the tedious approval process includes stability, sterility, and beyond-use date (BUD) testing.
Transfer prescriptions carry a high audit risk due to the additional documentation required based on state regulations.
On March 29, 2022, the CDC and FDA issued press releases to provide updated COVID-19 vaccine recommendations.
Pharmacies, big and small, may find themselves on the probing end of a hacker’s criminal scheme designed to access and steal protected health information (PHI).
Medicare has strict coverage qualifications and limitations for items covered by Part B.
If your pharmacy dispenses Actiq®, Fentora®, Subsys®, or other medications which fall under the TIRF program, now is a good time to evaluate your compliance with all TIRF REMS requirements.